Table 1.
Objective response rate
| Nivolumab plus ipilimumab (N=46) |
|
| All treated patients | |
| Objective response rate (95% CI), % | 17.4 (7.8 to 31.4) |
| Disease control rate (95% CI), %* | 58.7 (43.2 to 73.0) |
| Best overall response, n (%) | |
| Complete response | 0 |
| Partial response | 8 (17.4) |
| Stable disease | 19 (41.3) |
| Progressive disease | 14 (30.4) |
| Not evaluable/available† | 5 (10.9) |
| Patients with measurable tumor PD-L1 expression | |
| Objective response rate (95% CI), % | |
| PD-L1 ≥1% | 12.5 (0.3 to 52.7) |
| PD-L1 <1% | 14.3 (3.0 to 36.3) |
*Proportion of patients with a best overall response of complete response, partial response, or stable disease.
†Patients were considered not evaluable or available if either no imaging/measurement was done at a specific time point or if only a subset of lesion measurements were done at an assessment.
PD-L1, programmed death ligand 1.